- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06291480
Music Therapy After Stroke (Subacute Phase)
Music Therapy After Stroke (Subacute Phase): Assessing the Impact of Motivation and Neuroplasticity on Recovery of Upper-limb Impairment and Attention Deficits
The goal of this longitudinal, single-subject study is to investigate the role of motivation in music therapy for stroke patients within the subacute phase, who experience upper limb and/or attention deficits. The main questions it aims to answer are:
- Does music therapy increase patient's motivation to rehabilitate?
- Do increases in motivation correlate with functional improvements, in particular upper limb and/or attention skills?
Participants will receive up to 9 music therapy sessions within 3-5 weeks, with functional assessments before and after each period. Each participant serves as their own comparison: researchers will compare a period with standard care only (control phase) to a period with music therapy plus standard care (intervention phase), the order of which will be randomized in advance.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: Stroke is a highly disabling condition, for which music therapy is regularly used in rehabilitation. Motivation is considered to be a mechanism for functional improvements, including in neurologic music therapy (NMT), likely due to potential mood improvements, but it is not generally explicitly investigated. This motivation level may in turn affect not only functional outcomes and subjective well-being, but also adherence to other rehabilitation therapies.
Objectives: The primary goal of the study is to investigate motivation as an underlying mechanism of neurologic music therapy (NMT) for stroke patients experiencing upper-limb impairments and/or cognitive deficits, in the sub-acute phase of stroke. A secondary goal is to assess NMT-related changes in motor function, cognitive outcomes, and self-reported measures of well-being.
The hypothesis is that NMT will increase motivation, and that increased motivational state will positively affect functioning in both motor and/or cognitive domains.
Study design: The study has a longitudinal, single-subject design; as stroke patients are not a homogenous group, this design is adopted to control for expected within-subject variations. To account for variability in brain damage that is caused by stroke, each subject thus serves as their own control, and a longitudinal, repeated-measures design is selected. Participants will be randomized into two groups for a cross-over design, either receiving the intervention or the control phase first or vice versa, which counters order effects and assesses intervention effectiveness (as part of the secondary goals).
All subjects will receive NMT targeting both upper- limb movement and attention. All participants will receive a target of 9 NMT sessions (participants who complete a minimum of 6 sessions will be included in the analysis) over 3-6 weeks (depending on the rehabilitation trajectory, as subacute patients generally are admitted for a minimum of ± 6 and a maximum of 16 weeks), aiming for an average of 3 sessions per week, but adjusted to a patient's expected length of stay and ability, using a tailored approach.
Participants will receive three measurements. A baseline measure (TP1), on the first week of the rehabilitation trajectory, a second measure (TP2) either after the treatment/intervention period or control/ care as usual period (depending on the randomisation) and a post-treatment (TP3). The time interval between TP1- TP2 and TP2-TP3 are at least 21 days (3 weeks), with a margin of maximum 4-7 days, depending on their expected length of stay in the care facility.
Study population: In order to be eligible to participate in the study, a participant should be above 18 years of age and have had their first-ever supratentorial stroke between 2 weeks and up to 6 months before enrollment. Moreover, participants will have a referral for a paretic upper limb, i.e., partial loss of the capacity to carry out a voluntary upper limb movement and/or difficulty with attention/concentration, (e.g., complaints of being easily distractible, or unable to focus on a specific task in the presence of competing information, or complain of decline in attention). Participants must be able to receive music therapy for a minimum of 2-3 sessions per week, aiming for a total of 9 sessions over a minimum of three weeks, reducing this to 6 sessions in 2 weeks if required. The frequency of sessions is based on their ability and expected length of stay. Good command of the Dutch or English language is also a prerequisite for participation.
Participants will be excluded if this is not their first stroke or if a second stroke occurs during their stay. Further exclusion criteria are the following: i) upper limb paralysis as assessed by a score < 2 points on the Medical Research Scale (MRC) for muscle strength; ii) severe behavioural and/or cognitive problems preventing understanding or carrying out instructions or risk of dementia (a score <21 on the Mini-mental state examination; MMSE); iii) severe communication problems, e.g., severe aphasia and/or apraxia of speech; iv) known psychiatric, substance abuse, or neurological comorbidity. For participants who score <24 on the MMSE, a follow-up check will be carried out for a possible dementia diagnosis which would retrospectively lead to exclusion.
Sample size: In a previous study, 40 stroke patients in the sub-acute phase were allocated to either twenty 30-minute sessions of music-supported therapy (N = 20; 4 withdrew/excluded; 16 in final analysis) or twenty additional sessions of conventional therapy (N = 20; 2 withdrew/excluded; 18 in final analysis). The study found a significant correlation (r = .562, p = .024) between patients' intrinsic motivation to engage in musical activities as measured by the BMRQ at baseline and improvement of upper-limb function as measured by the Action Research Arm Test (ARAT) at 3 months, which was not found in the comparator of occupational/physical therapy (r = -.305, p < .21), with a significant difference between correlations (z = 2.4, p < .05). Using G power 3 analysis, the investigators estimated that 18 participants are needed to observe a similar effect size for a sufficiently powered study (α=0.05 and (1-β)=0.8; ρ H1 = 0.56). This indicates that 20 participants completing the entire protocol would be required to observe an effect of motivation in music therapy, with an expected attrition/missing data rate of 10-20%. This sample size is similar to the number of participants used in studies showing an effect for our secondary objectives, ranging from 14-20 participants, on the effects of music therapy on motor function, cognition, and psychological wellbeing. Recruitment will continue until 20 participants have completed the protocol.
Intervention: The intervention condition will consist of a target of up to 9 sessions in total, administered over an average of 5 weeks, but may span from 2 to 8 weeks according to the patient's length of stay at the Leo Polak Stroke Rehabilitation Centre. All music therapy interventions will be delivered by a registered music therapist. The protocol aims for participants to receive a minimum of two sessions per week over the duration of the study enrollment. However, this schedule may not be possible in every case due to the participants' length of stay. Participants who complete a minimum of 6 sessions will be included in the final analyses. The number of sessions each participant receives will be recorded and treated as a variable systematically recorded, and the number of sessions will be accounted for in the statistical analysis.
Main parameters/ endpoints: The main parameters of the study focus on the differences in motivation levels of participants as the result of applying NMT techniques in the subacute phase of stroke, comparing within-subject differences between changes related to the intervention and the control period. The motivation level of participants will be measured using the BMQ-S [patient-rated] as state-level motivation. The secondary parameters relate to behavioural outcomes of upper limb, and cognitive functions, as well as self-reported measures of well-being following NMT for within-participant comparisons between the intervention and control period.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rebecca Schaefer, PhD
- Phone Number: +31 71 527 6748
- Email: r.s.schaefer@fsw.leidenuniv.nl
Study Contact Backup
- Name: Theo Dimitriadis, MA
- Phone Number: +30625104076
- Email: tdimitriadis@fsw.leidenuniv.nl
Study Locations
-
-
Nederland
-
Amsterdam, Nederland, Netherlands, 1069BW
- Recruiting
- Leo Polak Rehabilitation centre
-
Contact:
- Theo Dimitriadis, MSc
- Email: tdimitriadis@amstelring.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects had their first-ever supratentorial stroke between 2 weeks and up to 6 months before enrolment
- Paretic upper limb and/or attention/ concentration problems
- Ability to communicate in Dutch or English
Exclusion Criteria:
- Severe (global) aphasia
- paralysis of upper limb
- severe cognitive decline (MMSE <24)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Music Therapy + Care as Usual
9 music therapy sessions within 2-5 weeks during stroke rehabilitation, in addition to care as usual.
|
Music therapy focused on cognitive and motor rehabilitation after stroke (subacute phase).
|
No Intervention: Care as Usual
2-5 weeks of care as usual, without music therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motivation: Brain Injury Rehabilitation Trust Motivation Questionnaire (BMQ-S) [self-reported]
Time Frame: This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
The BMQ-S is a 34-item questionnaire, which measures the motivation levels of the stroke survivor, using a 4-point likert scale (always, often, sometimes, never).
Items that involve different factors such as anhedonia, perseveration, poor initiation, or distractibility, are summed to create a total score from 34 to 136, with higher scores representing greater difficulties in motivation.
|
This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motor Function: Action Research Arm Test (ARAT)
Time Frame: This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
The Action Research Arm Test (ARAT) is a 19-item observational measure used by healthcare professionals to assess upper extremity performance (coordination, dexterity, and functioning) in stroke recovery and brain injury. Items comprising the ARAT are categorized into four subscales (grasp, grip, pinch, and gross movement) and arranged in order of decreasing difficulty, with the most difficult task examined first, followed by the least difficult task. Performance on each item is rated on a 4-point ordinal scale ranging from: 3) Performs test normally 2) Completes test, but takes abnormally long or has great difficulty 1) Performs test partially 0) Can perform no part of test The maximum score on the ARAT is 57 points (possible range 0 to 57). A higher score indicates better functioning in the upper extremity. |
This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
Motor Function: Barthel Index (BI)
Time Frame: This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
The Barthel Index (BI) measures the extent to which somebody can function independently and has mobility in their activities of daily living (ADL) i.e. feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation and stair climbing. The ten items are scored on a 4/5-item Likert scale, and then a final score is calculated by summing the points awarded to each functional skill. This allows the examiner to measure a patient's functional disability by quantifying their performance. Minimum value: 0, maximum value: 20. The higher the score, the more independent the patient is in completing the measured ADLs. Higher scores also indicate the patient is more likely to return home, with varying degrees of assistance, following hospital discharge. The lower the score, the more dependent the patient is with ADL completion. |
This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
Cognition: Cancellation Wechsler Adult Intelligence Scale (WAIS-IV)
Time Frame: This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
The WAIS-IV cancellation test measures, amongst others, processing speed, visuospatial attention and/or neglect. A score is constructed based on how many targets or false alarms are indicated within 45s. More missed targets or false alarms indicate worse performance. The test does not explicitly list minimum or maximum scores due to the nature of the test being a scaled score rather than a fixed value. However, based on the understanding that scaled scores typically range from 1 to 19, with lower scores indicating more cognitive difficulties and higher scores indicating fewer difficulties, investigators infer that the lowest possible scaled score would be around 1, and the highest possible scaled score would be around 19. This is assuming that the test follows typical scoring conventions where the mean is approximately 10 and the standard deviation is about 3 |
This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
Cognition: Color-Word Interference Test, also known as Stroop test
Time Frame: This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
The Stroop test can be used to measure a person's processing speed and interference, testing overall executive processing abilities. It is based on the difference of reading and naming ink colors of a word name when the name and color are different than when they are the same. The interference is calculated by subtracting congruent trials (only naming colors or words) with interference trials (words printed in colored ink), taking into account mistakes, with less difference in time o fewer mistakes indicating better performance. |
This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
Cognition: WAIS IV Digit Span Test - Forward and Backward
Time Frame: This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
The Digit Sequencing or Digit Span test is one of the main tools developed to measure one's working memory and attention. The Digit Span score is the length of the longest correctly repeated sequence, either forward or backward. The number of sequences of correctly recalled digits is summed to produce a raw score between 0 and 8 for each subtest, where a higher score indicates better performance. |
This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
Cognition: Verbal Fluency Test
Time Frame: This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
A verbal fluency test is a kind of test in which a participant is asked to produce as many words as possible from a category in a given time (usually 60 seconds). The phonemic verbal fluency test consists of producing as many words as possible within one minute for 3 letters (using cross-validated versions that are different at each time point). The total number of valid responses across trials excluding repeats are added to produce a total score, where a higher score indicates better performance. |
This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
Cognition: Trail Making Test (TMT)
Time Frame: This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
The trail making test assesses a wide variety of cognitive processes including attention, visual search and scanning, sequencing and shifting, psychomotor speed, abstraction, flexibility, ability to execute and modify a plan of action, and ability to switch instructions. The Trail Making Test is measured in time over 5 trials. The final score is trial 2 (number/letter-switching) trial 1 (only using numbers). The interference is scored based on the difference between trials 1 and 2, where a larger time difference indicates more interference. |
This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motivation to engage in musical activities: Barcelona Music Reward Questionnaire (BMRQ)
Time Frame: This outcome measure will be administered once, during the baseline Test Point (TP1) (week 1).
|
The BMRQ measures intrinsic motivation to engage in musical activities and experience musical reward. The BMRQ examines five main facets that characterize musical reward experience in individuals: musical seeking, emotion evocation, mood regulation, social reward, and sensory-motor. The BMRQ is a 20-item questionnaire in which participants rate on a 5-point scale the extent to which they agree with statements indicating their degree of musical reward across five dimensions: musical seeking, emotion evocation, mood regulation, sensory-motor, and social reward. Scores are constructed by summing the likert scale score, ranging from 20-100. |
This outcome measure will be administered once, during the baseline Test Point (TP1) (week 1).
|
Quality of Life: EuroQol-5 (EQ-5D-5L)
Time Frame: This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
The EQ-5D-5L is an outcome measure for measuring the health and health-related quality of life, assessing five important dimensions: mobility, self-care, daily activities, pain and fear/depression (5D) represented in 5 questions.
Score range from 1-5 per question where a higher number is a worse outcome (score range between 1 and 25), and a visual analogue scale from 0-100 where for both a higher number is a better outcome.
|
This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
Mood: Depression Anxiety Stress Scale-21 (DASS-21)
Time Frame: This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
The Depression, Anxiety and Stress Scale - 21 Items (DASS-21) is a set of three self-report scales designed to measure the emotional states of depression, anxiety and stress. Scores of the Depression Anxiety Stress Scale are added up per category (depression, anxiety and stress): Depression symptoms related items: 3, 5, 10, 13, 16, 17, 21 (range from 0-21) Anxiety disorder-related items: 2, 4, 7, 9, 15, 19, 20 (range from 0-21) Stress-related items: 1, 6, 8, 11, 12, 14, 18 (range from 0-21), where a higher score indicates a worse outcome for all domains. |
This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
Mood: Visual Analogue Mood Scale (VAMS)
Time Frame: Within 10 minutes before the start of each music therapy session (pre intervention) and immediately after each music therapy session (post intervention).
|
The VAMS consists of a 180-mm line having two circles at its respective ends that represent two opposite moods - the upper circle containing a stylized "happy" face, the lower a "sad" one.
The VAMS thus allows measuring euthymia/dysthymia along a continuum.
Scores are measured by locating responses on the line (min 0 - max 180).
|
Within 10 minutes before the start of each music therapy session (pre intervention) and immediately after each music therapy session (post intervention).
|
Personality Traits: The Big Five Index-Extra Short Form (BFI-2-XS)
Time Frame: This outcome measure will be administered once, during the baseline Test Point (TP1) (week 1).
|
The BFI-2 is a measure of the Big Five personality domains (labelled as Extraversion, Agreeableness, Conscientiousness, Negative Emotionality, and Open-Mindedness) through 15 more specific question items that are scored on a Likert scale from 1-5 and combined per personality domain (score range is 3-15 per domain). Higher scores indicate a greater tendency toward that personality trait (e.g., higher values of Conscientiousness indicate propensity to orderliness, industriousness, and dutifulness, whereas higher values of Negative Emotionality indicate propensity to anxiety, depression, and lability). |
This outcome measure will be administered once, during the baseline Test Point (TP1) (week 1).
|
Optimism: Life Orientation Test- Revised (LOT-R)
Time Frame: This outcome measure will be administered once, during the baseline Test Point (TP1) (week 1).
|
The LOT-R will be used to assess dispositional optimism. The 10-item LOT-R comprises a combination of direct scored, reverse-scored and filler items. All items are presented on 5-point scales, from 0 (I disagree a lot) to 4 (I agree a lot). Scores can range from 0-24, interpreted in categories, namely: 0-13: Low Optimism (High Pessimism); 14-18: Moderate Optimism; 19-24: High Optimism (Low Pessimism). |
This outcome measure will be administered once, during the baseline Test Point (TP1) (week 1).
|
Brief self-report of therapy expectations and satisfaction with treatment
Time Frame: This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
Brief questionnaire targeting the expectations of the participant regarding music therapy, but also other disciplines, such as physical therapy, psychology, occupational therapy, etc A likert-scale is used to indicate the expectations of the participant, from 0 (totally disagree) to 4 (totally agree), with the higher scores indicating that the patient expects that a particular discipline will/will not help them improve/ rehabilitate optimally.
|
This outcome measure will be administered at 3 different time points (TP): Baseline/TP1 (week1), Mid-Trial/TP2 (week 4) and Final Measures/TP3 (week 7).
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Hanneke Hulst, PhD, Leiden University
Publications and helpful links
General Publications
- Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. No abstract available.
- Altenmuller E, Marco-Pallares J, Munte TF, Schneider S. Neural reorganization underlies improvement in stroke-induced motor dysfunction by music-supported therapy. Ann N Y Acad Sci. 2009 Jul;1169:395-405. doi: 10.1111/j.1749-6632.2009.04580.x.
- Schneider S, Schonle PW, Altenmuller E, Munte TF. Using musical instruments to improve motor skill recovery following a stroke. J Neurol. 2007 Oct;254(10):1339-46. doi: 10.1007/s00415-006-0523-2. Epub 2007 Jan 27.
- Kwakkel G, Kollen BJ, van der Grond J, Prevo AJ. Probability of regaining dexterity in the flaccid upper limb: impact of severity of paresis and time since onset in acute stroke. Stroke. 2003 Sep;34(9):2181-6. doi: 10.1161/01.STR.0000087172.16305.CD. Epub 2003 Aug 7.
- Oyake K, Suzuki M, Otaka Y, Tanaka S. Motivational Strategies for Stroke Rehabilitation: A Descriptive Cross-Sectional Study. Front Neurol. 2020 Jun 10;11:553. doi: 10.3389/fneur.2020.00553. eCollection 2020.
- Barker-Collo SL, Feigin VL, Lawes CM, Parag V, Senior H, Rodgers A. Reducing attention deficits after stroke using attention process training: a randomized controlled trial. Stroke. 2009 Oct;40(10):3293-8. doi: 10.1161/STROKEAHA.109.558239. Epub 2009 Jul 23.
- Oddy M, Cattran C, Wood R. The development of a measure of motivational changes following acquired brain injury. J Clin Exp Neuropsychol. 2008 Jul;30(5):568-75. doi: 10.1080/13803390701555598.
- Baltazar, M., Västfjäll, D., Asutay, E., Koppel, L., & Saarikallio, S. (2019). Is it me or the music? Stress reduction and the role of regulation strategies and music. Music & Science, 2. https://doi.org/10.1177/2059204319844161
- Burger B, Thompson MR, Luck G, Saarikallio S, Toiviainen P. Influences of rhythm- and timbre-related musical features on characteristics of music-induced movement. Front Psychol. 2013 Apr 12;4:183. doi: 10.3389/fpsyg.2013.00183. eCollection 2013.
- Dimitriadis T, Della Porta D, Perschl J, Evers AWM, Magee WL, Schaefer RS. Motivation and music interventions in adults: A systematic review. Neuropsychol Rehabil. 2023 Jun 21:1-30. doi: 10.1080/09602011.2023.2224033. Online ahead of print.
- Dwan T, Ownsworth T. The Big Five personality factors and psychological well-being following stroke: a systematic review. Disabil Rehabil. 2019 May;41(10):1119-1130. doi: 10.1080/09638288.2017.1419382. Epub 2017 Dec 22.
- Fine, E. & Delis, D. (2011) Delis-Kaplan Executive Functioning System. In J. S. Kreutzer, J. DeLuca, and B. Caplan (Eds) Encyclopedia of Clinical Neuropsychology,. New York, NY: Springer, pp. 796-801. doi: 10.1007/978-0-387-79948- 3_1539.
- Fujioka T, Dawson DR, Wright R, Honjo K, Chen JL, Chen JJ, Black SE, Stuss DT, Ross B. The effects of music-supported therapy on motor, cognitive, and psychosocial functions in chronic stroke. Ann N Y Acad Sci. 2018 May 24. doi: 10.1111/nyas.13706. Online ahead of print.
- Grau-Sanchez J, Duarte E, Ramos-Escobar N, Sierpowska J, Rueda N, Redon S, Veciana de Las Heras M, Pedro J, Sarkamo T, Rodriguez-Fornells A. Music-supported therapy in the rehabilitation of subacute stroke patients: a randomized controlled trial. Ann N Y Acad Sci. 2018 Apr 1. doi: 10.1111/nyas.13590. Online ahead of print.
- Grau-Sanchez J, Munte TF, Altenmuller E, Duarte E, Rodriguez-Fornells A. Potential benefits of music playing in stroke upper limb motor rehabilitation. Neurosci Biobehav Rev. 2020 May;112:585-599. doi: 10.1016/j.neubiorev.2020.02.027. Epub 2020 Feb 21.
- Kim SY, Kim JM, Stewart R, Kang HJ, Kim SW, Shin IS, Park MS, Cho KH, Yoon JS. Influences of personality traits on quality of life after stroke. Eur Neurol. 2013;69(3):185-92. doi: 10.1159/000345699. Epub 2013 Jan 10.
- Mas-Herrero, E., Marco-Pallares, J., Lorenzo-Seva, U., Zatorre, R. J., & Rodriguez-Fornells, A. (2012). Individual differences in music reward experiences. Music Perception: An Interdisciplinary Journal, 31(2), 118-138.
- Olgiati E, Russell C, Soto D, Malhotra P. Motivation and attention following hemispheric stroke. Prog Brain Res. 2016;229:343-366. doi: 10.1016/bs.pbr.2016.06.011. Epub 2016 Sep 16.
- Raglio A, Zaliani A, Baiardi P, Bossi D, Sguazzin C, Capodaglio E, Imbriani C, Gontero G, Imbriani M. Active music therapy approach for stroke patients in the post-acute rehabilitation. Neurol Sci. 2017 May;38(5):893-897. doi: 10.1007/s10072-017-2827-7. Epub 2017 Jan 30.
- Ripolles P, Rojo N, Grau-Sanchez J, Amengual JL, Camara E, Marco-Pallares J, Juncadella M, Vaquero L, Rubio F, Duarte E, Garrido C, Altenmuller E, Munte TF, Rodriguez-Fornells A. Music supported therapy promotes motor plasticity in individuals with chronic stroke. Brain Imaging Behav. 2016 Dec;10(4):1289-1307. doi: 10.1007/s11682-015-9498-x.
- Schaefer RS. Auditory rhythmic cueing in movement rehabilitation: findings and possible mechanisms. Philos Trans R Soc Lond B Biol Sci. 2014 Dec 19;369(1658):20130402. doi: 10.1098/rstb.2013.0402.
- Stone SP, Ali B, Auberleek I, Thompsell A, Young A. The Barthel index in clinical practice: use on a rehabilitation ward for elderly people. J R Coll Physicians Lond. 1994 Sep-Oct;28(5):419-23.
- Street AJ, Magee WL, Odell-Miller H, Bateman A, Fachner JC. Home-based neurologic music therapy for upper limb rehabilitation with stroke patients at community rehabilitation stage-a feasibility study protocol. Front Hum Neurosci. 2015 Sep 23;9:480. doi: 10.3389/fnhum.2015.00480. eCollection 2015.
- Street, A., Fachner, J. & Magee, W. (2019) Upper limb rehabilitation in chronic stroke using neurologic music therapy: Two contrasting case studies to inform on treatment delivery and patient suitability, Nordic Journal of Music Therapy, 28:5, 382-404, DOI: 10.1080/08098131.2019.1606848
- Thaut, M. H., & Hoemberg, V. (Eds.). (2014). Handbook of neurologic music therapy. Oxford University Press.
- Tong Y, Forreider B, Sun X, Geng X, Zhang W, Du H, Zhang T, Ding Y. Music-supported therapy (MST) in improving post-stroke patients' upper-limb motor function: a randomised controlled pilot study. Neurol Res. 2015 May;37(5):434-40. doi: 10.1179/1743132815Y.0000000034. Epub 2015 Apr 27.
- Verrienti G, Raccagni C, Lombardozzi G, De Bartolo D, Iosa M. Motivation as a Measurable Outcome in Stroke Rehabilitation: A Systematic Review of the Literature. Int J Environ Res Public Health. 2023 Feb 26;20(5):4187. doi: 10.3390/ijerph20054187.
- van Alphen R, Stams GJJM, Hakvoort L. Musical Attention Control Training for Psychotic Psychiatric Patients: An Experimental Pilot Study in a Forensic Psychiatric Hospital. Front Neurosci. 2019 Jun 7;13:570. doi: 10.3389/fnins.2019.00570. eCollection 2019.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL78853.058.22 / STRUM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke (CVA) or TIA
-
AIRx Health, Inc.Stanford UniversityNot yet recruitingHypertension | Stroke (CVA) or TIAUnited States
-
Riphah International UniversityCompletedStroke (CVA) or TIAPakistan
-
Centre Hospitalier Universitaire de NiceRecruiting
-
Chinese University of Hong KongRecruiting
-
Montefiore Medical CenterWithdrawnStroke (CVA) or TIA
-
Riphah International UniversityCompleted
-
NHS Greater Glasgow and ClydeNot yet recruitingMemory Impairment | Stroke (CVA) or TIA
-
Medical University of South CarolinaRecruitingStroke Sequelae | Motivation | Apathy | Stroke (CVA) or TIA | Stroke/Brain Attack | AbuliaUnited States
-
VASCage GmbHMedical University InnsbruckCompleted
-
Beijing Tiantan HospitalAlain Medical (Beijing) Co., Ltd.RecruitingIntracranial Arteriosclerosis | Stroke (CVA) or TIAChina
Clinical Trials on Neurologic Music Therapy
-
Istanbul Medeniyet UniversityUnknown
-
University of TorontoColorado State University; Poudre Valley Health System Fort Collins COCompletedContinuous Rhythmic Auditory Stimulation | Intermittent Rhythmic Auditory Stimulation
-
University of Colorado, DenverNational Center for Complementary and Integrative Health (NCCIH)Recruiting
-
University of TorontoColorado State UniversityCompletedHemispatial Neglect
-
Case Comprehensive Cancer CenterCompletedMultiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin LymphomaUnited States
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteCompletedAutonomic Nervous System Imbalance | Hypothalamic Pituitary Adrenal Axis SuppressionUnited States
-
Wayne State UniversityCompletedNeurological DisordersUnited States
-
Icahn School of Medicine at Mount SinaiCompletedSARS-CoV 2 | Dyspnea | Post Covid-19 RespiratoryUnited States
-
Icahn School of Medicine at Mount SinaiCompleted
-
Children's Healthcare of AtlantaCompletedRespiratory Syncytial Virus InfectionsUnited States